208 related articles for article (PubMed ID: 38071314)
1. Evaluation of a new fusion antigen, cd loop and HAP2-GCS1 domain (cd-HAP) of Plasmodium falciparum Generative Cell Specific 1 antigen formulated with various adjuvants, as a transmission blocking vaccine.
Pourhashem Z; Nourani L; Sani JJ; Yousefi H; Pirahmadi S; Sabouri M; Raz A; Djadid ND; Zakeri S; Mehrizi AA
Malar J; 2023 Dec; 22(1):374. PubMed ID: 38071314
[TBL] [Abstract][Full Text] [Related]
2. Malaria transmission blocking activity of Anopheles stephensi alanyl aminopeptidase N antigen formulated with MPL, CpG, and QS21 adjuvants.
Pourhashem Z; Nourani L; Pirahmadi S; Yousefi H; J Sani J; Raz A; Zakeri S; Dinparast Djadid N; Abouie Mehrizi A
PLoS One; 2024; 19(7):e0306664. PubMed ID: 38968270
[TBL] [Abstract][Full Text] [Related]
3. Limited genetic diversity and purifying selection in Iranian Plasmodium falciparum Generative Cell Specific 1 (PfGCS1), a potential target for transmission-blocking vaccine.
Mehrizi AA; Zakeri S; Djadid ND
Infect Genet Evol; 2014 Mar; 22():150-6. PubMed ID: 24462906
[TBL] [Abstract][Full Text] [Related]
4. Cell-traversal protein for ookinetes and sporozoites (CelTOS) formulated with potent TLR adjuvants induces high-affinity antibodies that inhibit Plasmodium falciparum infection in Anopheles stephensi.
Pirahmadi S; Zakeri S; A Mehrizi A; D Djadid N; Raz AA; J Sani J; Abbasi R; Ghorbanzadeh Z
Malar J; 2019 Apr; 18(1):146. PubMed ID: 31014347
[TBL] [Abstract][Full Text] [Related]
5. Combining Monophosphoryl Lipid A (MPL), CpG Oligodeoxynucleotide (ODN), and QS-21 Adjuvants Induces Strong and Persistent Functional Antibodies and T Cell Responses against Cell-Traversal Protein for Ookinetes and Sporozoites (CelTOS) of Plasmodium falciparum in BALB/c Mice.
Pirahmadi S; Zakeri S; Mehrizi AA; Djadid ND; Raz AA; Sani JJ
Infect Immun; 2019 Jun; 87(6):. PubMed ID: 30936155
[No Abstract] [Full Text] [Related]
6. Functional comparison of Plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay.
Miura K; Takashima E; Deng B; Tullo G; Diouf A; Moretz SE; Nikolaeva D; Diakite M; Fairhurst RM; Fay MP; Long CA; Tsuboi T
Infect Immun; 2013 Dec; 81(12):4377-82. PubMed ID: 24042109
[TBL] [Abstract][Full Text] [Related]
7. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
Arakawa T; Komesu A; Otsuki H; Sattabongkot J; Udomsangpetch R; Matsumoto Y; Tsuji N; Wu Y; Torii M; Tsuboi T
Infect Immun; 2005 Nov; 73(11):7375-80. PubMed ID: 16239536
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
Lalitha PV; Biswas S; Pillai CR; Saxena RK
Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
[TBL] [Abstract][Full Text] [Related]
9. Alga-produced malaria transmission-blocking vaccine candidate Pfs25 formulated with a human use-compatible potent adjuvant induces high-affinity antibodies that block Plasmodium falciparum infection of mosquitoes.
Patra KP; Li F; Carter D; Gregory JA; Baga S; Reed SG; Mayfield SP; Vinetz JM
Infect Immun; 2015 May; 83(5):1799-808. PubMed ID: 25690099
[TBL] [Abstract][Full Text] [Related]
10. ELISA units, IgG subclass ratio and avidity determined functional activity of mouse anti-Pfs230 antibodies judged by a standard membrane-feeding assay with Plasmodium falciparum.
Miura K; Deng B; Wu Y; Zhou L; Pham TP; Diouf A; Wu CK; Lee SM; Plieskatt JL; Morin MJ; Long CA
Vaccine; 2019 Apr; 37(15):2073-2078. PubMed ID: 30850239
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of the profiles of IgG subclass-specific responses to Plasmodium falciparum apical membrane antigen-1 and merozoite surface protein-1 in naturally exposed individuals living in malaria hypoendemic settings, Iran.
Rouhani M; Zakeri S; Mehrizi AA; Djadid ND
Malar J; 2015 Feb; 14():58. PubMed ID: 25652589
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.
Tamborrini M; Stoffel SA; Westerfeld N; Amacker M; Theisen M; Zurbriggen R; Pluschke G
Malar J; 2011 Dec; 10():359. PubMed ID: 22166048
[TBL] [Abstract][Full Text] [Related]
13. Transmission-blocking activity of antibodies to Plasmodium falciparum GLURP.10C chimeric protein formulated in different adjuvants.
Roeffen W; Theisen M; van de Vegte-Bolmer M; van Gemert G; Arens T; Andersen G; Christiansen M; Sevargave L; Singh SK; Kaviraj S; Sauerwein R
Malar J; 2015 Nov; 14():443. PubMed ID: 26552428
[TBL] [Abstract][Full Text] [Related]
14. Potent malaria transmission-blocking antibody responses elicited by Plasmodium falciparum Pfs25 expressed in Escherichia coli after successful protein refolding.
Kumar R; Angov E; Kumar N
Infect Immun; 2014 Apr; 82(4):1453-9. PubMed ID: 24421036
[TBL] [Abstract][Full Text] [Related]
15. Identification of domains within Pfs230 that elicit transmission blocking antibody responses.
Tachibana M; Miura K; Takashima E; Morita M; Nagaoka H; Zhou L; Long CA; Richter King C; Torii M; Tsuboi T; Ishino T
Vaccine; 2019 Mar; 37(13):1799-1806. PubMed ID: 30824357
[TBL] [Abstract][Full Text] [Related]
16. Poly(I:C) adjuvant strongly enhances parasite-inhibitory antibodies and Th1 response against Plasmodium falciparum merozoite surface protein-1 (42-kDa fragment) in BALB/c mice.
Mehrizi AA; Rezvani N; Zakeri S; Gholami A; Babaeekhou L
Med Microbiol Immunol; 2018 Apr; 207(2):151-166. PubMed ID: 29397427
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity in the acquisition of naturally acquired antibodies to cell-traversal protein for ookinetes and sporozoites (CelTOS) and thrombospondin-related adhesion protein (TRAP) of Plasmodium falciparum in naturally infected patients from unstable malaria areas in Iran.
Pirahmadi S; Zakeri S; Mehrizi AA; Karimi L; Djadid ND
Acta Trop; 2019 Feb; 190():365-374. PubMed ID: 30543766
[TBL] [Abstract][Full Text] [Related]
18. Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice.
Coelho CH; Gazzinelli-Guimaraes PH; Howard J; Barnafo E; Alani NAH; Muratova O; McCormack A; Kelnhofer E; Urban JF; Narum DL; Anderson C; Langhorne J; Nutman TB; Duffy PE
Vaccine; 2019 Feb; 37(8):1038-1045. PubMed ID: 30685251
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of dimorphic and C-terminal fragments of Plasmodium falciparum MSP2 formulated with different adjuvants in mice.
Balam S; Jafarshad A; Servis C; Frank G; Reed S; Pink R; Druilhe P; Spertini F; Corradin G
Vaccine; 2016 Mar; 34(13):1566-1574. PubMed ID: 26874325
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
